Alex Mercer
YOU?
Author Swipe
View article: #2883 Kidney outcomes and effects of proteinuria in Alport syndrome: a longitudinal analysis of 1175 patients from the UK National Registry of Rare Kidney Diseases (RaDaR)
#2883 Kidney outcomes and effects of proteinuria in Alport syndrome: a longitudinal analysis of 1175 patients from the UK National Registry of Rare Kidney Diseases (RaDaR) Open
Background and Aims Alport syndrome (AS) is often characterised by pathogenic variants in type IV collagen genes COL4A3/4/5. Previous genotype-phenotype studies have shown patients with certain genotypes reach kidney failure (KF) at a youn…
View article: WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL
WCN25-1884 SPARSENTAN (SPAR) AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE SPARTAN TRIAL Open
View article: Long-term outcomes of patients with IgA nephropathy in the German CKD cohort
Long-term outcomes of patients with IgA nephropathy in the German CKD cohort Open
Background The importance of albuminuria as opposed to proteinuria in predicting kidney outcomes in primary immunoglobulin A nephropathy (IgAN) is not well established. Methods From 2010 to 2012, 421 patients with biopsy-proven IgAN have b…
View article: #367 PROTECT and NefIgArd two-year proteinuria and eGFR outcomes in adults with IgA nephropathy: matching-adjusted indirect comparison
#367 PROTECT and NefIgArd two-year proteinuria and eGFR outcomes in adults with IgA nephropathy: matching-adjusted indirect comparison Open
Background and Aims Immunoglobulin A (IgA) nephropathy is a rare kidney disorder characterized by deposition of IgA in the glomeruli causing progressive loss of kidney function and increased risk of kidney failure. In the absence of a head…
View article: #368 Matching-Adjusted Indirect Comparisons of eGFR slopes in the PROTECT study with UK RaDaR IgA nephropathy population and the control arm of NefIgArd
#368 Matching-Adjusted Indirect Comparisons of eGFR slopes in the PROTECT study with UK RaDaR IgA nephropathy population and the control arm of NefIgArd Open
Background and Aims Immunoglobulin A nephropathy (IgAN) is a rare kidney disorder characterized by deposition of IgA in the glomeruli leading to an increased risk of kidney failure. The PROTECT clinical trial in IgAN was designed to determ…
View article: Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort
Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort Open
Background Focal segmental glomerulosclerosis (FSGS) can lead to kidney failure in adults. This study examines the progression of FSGS in the German Chronic Kidney Disease (GCKD) cohort. Methods The GCKD study (N = 5217), a prospective coh…
View article: WCN24-774 PRELIMINARY FINDINGS FROM THE PHASE 2 EPPIK STUDY OF SPARSENTAN IN PEDIATRIC PATIENTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES
WCN24-774 PRELIMINARY FINDINGS FROM THE PHASE 2 EPPIK STUDY OF SPARSENTAN IN PEDIATRIC PATIENTS WITH SELECTED PROTEINURIC GLOMERULAR DISEASES Open
Sparsentan (SPAR) is a novel, nonimmunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist (DEARA) approved by the US Food and Drug Administration for the treatment of adults with immunoglobulin A (IgA) nephropath…
View article: WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE)
WCN24-752 CONCOMITANT SPARSENTAN AND SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS (SGLT2is) IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN) IN THE PROTECT OPEN-LABEL EXTENSION (OLE) Open
Sparsentan (SPAR) is a novel, nonimmunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist (DEARA). In the ongoing PROTECT trial SPAR is compared to irbesartan in patients with IgAN. SGLT2is may slow disease progr…
View article: WCN24-773 SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL
WCN24-773 SPARSENTAN AS FIRST-LINE TREATMENT OF INCIDENT PATIENTS WITH IgA NEPHROPATHY: PRELIMINARY FINDINGS FROM THE SPARTAN TRIAL Open
Sparsentan (SPAR) is a novel, nonimmunosuppressive, single molecule dual endothelin angiotensin receptor antagonist (DEARA) approved by the US Food and Drug Administration for treatment of adults with IgA nephropathy (IgAN). SPARTAN is an …
View article: Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study Open
Patient enrollment in DUPLEX, the largest interventional study in FSGS to date, will enable important characterization of the treatment effect of sparsentan in a geographically broad and clinically diverse FSGS population.
View article: Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial Open
View article: #4503 ESTIMATING DELAY IN TIME TO KIDNEY FAILURE OR DEATH FOR TREATMENT EFFECTS ON PROTEINURIA IN IGA NEPHROPATHY
#4503 ESTIMATING DELAY IN TIME TO KIDNEY FAILURE OR DEATH FOR TREATMENT EFFECTS ON PROTEINURIA IN IGA NEPHROPATHY Open
Background and Aims Reduction in proteinuria is associated with lower risk of kidney failure (KF) in IgA nephropathy (IgAN) (Thompson et al, 2019). In phase 3 randomized controlled trials in IgAN patients, a treatment effect on proteinuria…
View article: #3067 ALPORT SYNDROME NATURAL HISTORY FROM THE RADAR REGISTRY: ASSOCIATIONS WITH GENE, VARIANT TYPE AND SEX
#3067 ALPORT SYNDROME NATURAL HISTORY FROM THE RADAR REGISTRY: ASSOCIATIONS WITH GENE, VARIANT TYPE AND SEX Open
Background and Aims Alport Syndrome (AS) is caused by pathogenic variants in COL4A3, COL4A4 & COL4A5 genes. The clinical course of AS can be highly variable, depending on gene affected, mutation type and Male (M) or Female (F) sex. Protein…
View article: #4057 SUPERIOR PROTEINURIA REDUCTION WITH SPARSENTAN IN IMMUNOGLOBULIN A NEPHROPATHY (IGAN): A PROTECT STUDY INTERIM ANALYSIS
#4057 SUPERIOR PROTEINURIA REDUCTION WITH SPARSENTAN IN IMMUNOGLOBULIN A NEPHROPATHY (IGAN): A PROTECT STUDY INTERIM ANALYSIS Open
Background and Aims IgAN is the most common glomerular disease worldwide. Despite optimized standard of care, most patients with IgAN progress to kidney failure within 10-15 years, consequently seriously affecting their quality of life and…
View article: #3057 OUTCOMES IN SRNS (FSGS) PATIENTS IN THE UK RADAR IDIOPATHIC NEPHROTIC SYNDROME REGISTRY AND THEIR RELATIONSHIP WITH TIME-AVERAGED PROTEINURIA
#3057 OUTCOMES IN SRNS (FSGS) PATIENTS IN THE UK RADAR IDIOPATHIC NEPHROTIC SYNDROME REGISTRY AND THEIR RELATIONSHIP WITH TIME-AVERAGED PROTEINURIA Open
Background and Aims Idiopathic Steroid Resistant Nephrotic Syndrome, SRNS (incorporating FSGS) is an important cause of proteinuric renal disease leading to kidney failure. Here we describe the outcomes of SRNS using the UK National Regist…
View article: #5142 THE NATURAL HISTORY OF FSGS IN THE GERMAN CHRONIC KIDNEY DISEASE (GCKD) COHORT
#5142 THE NATURAL HISTORY OF FSGS IN THE GERMAN CHRONIC KIDNEY DISEASE (GCKD) COHORT Open
Background and Aims FSGS is a heterogenic glomerular disease and a common cause of kidney failure in adults. Here we describe the natural history of individuals with FSGS in the German Chronic Kidney Disease (GCKD) cohort. Method From 2010…
View article: Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial Open
View article: IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study Open
View article: Maximizing the value of the open label extension phase of randomized clinical trials
Maximizing the value of the open label extension phase of randomized clinical trials Open
View article: Best Hillsborough Plumbing Experts in San Mateo
Best Hillsborough Plumbing Experts in San Mateo Open
At James Caccia Plumbing, we are proud to offer excellent plumbing services to Hillsborough residents. We hear a lot of questions and inquiries regarding the services that we offer, and we are happy to answer those questions and help our c…
View article: Best Palo Alto Plumbing Experts
Best Palo Alto Plumbing Experts Open
Having plumbing complications in your Palo Alto home? Call palo alto plumber now at (650) 376-6800 for the county’s top services! If you have just bought a home after being a renter for many years, all the structure’s appliances are yours …
View article: MO256THE TREATMENT EFFECT OF RAS BLOCKADE ON PROTEINURIA IN IGA NEPHROPATHY PATIENTS AS A SURROGATE FOR RENAL EVENTS AND DECLINE IN EGFR: AN ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
MO256THE TREATMENT EFFECT OF RAS BLOCKADE ON PROTEINURIA IN IGA NEPHROPATHY PATIENTS AS A SURROGATE FOR RENAL EVENTS AND DECLINE IN EGFR: AN ANALYSIS OF RANDOMIZED CONTROLLED TRIALS Open
Background and Aims Renin-Angiotensin System Blockade (RASB) is the cornerstone of standard-of-care in IgA nephropathy. Randomized controlled trials (RCTs) have shown the treatment benefit of RASB therapy on proteinuria and risk of renal f…
View article: MO246ESTIMATING DELAY IN TIME TO ESKD FOR TREATMENT EFFECTS ON PROTEINURIA IN IGA NEPHROPATHY AND FSGS*
MO246ESTIMATING DELAY IN TIME TO ESKD FOR TREATMENT EFFECTS ON PROTEINURIA IN IGA NEPHROPATHY AND FSGS* Open
Background and Aims Reduction in proteinuria is associated with lower risk of end-stage kidney disease (ESKD) in IgA nephropathy (Thompson et al, 2019) and focal segmental glomerulosclerosis (FSGS) (Troost et al, 2017). Sparsentan, a dual …
View article: Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis
Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis Open
View article: Clinical trial recommendations for potential Alport syndrome therapies
Clinical trial recommendations for potential Alport syndrome therapies Open
Alport syndrome is experiencing a remarkable increase in preclinical investigations. To proactively address the needs of the Alport syndrome community, as well as offer clarity for future clinical research sponsors, the Alport Syndrome Fou…
View article: Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)
Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial) Open
View article: Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy Open
IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course for progression to ESKD. The aim of this Kidney Health Initiative …
View article: TO013PROTEINURIA REDUCTION IN IGA NEPHROPATHY BY NEFECON, A TARGETED‑RELEASE FORMULATION OF BUDESONIDE - RESULTS FROM THE NEFIGAN TRIAL
TO013PROTEINURIA REDUCTION IN IGA NEPHROPATHY BY NEFECON, A TARGETED‑RELEASE FORMULATION OF BUDESONIDE - RESULTS FROM THE NEFIGAN TRIAL Open
View article: Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial Open
View article: Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis
Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis Open